When is Satralizumab (Enspryng) expected to be approved for myelin oligodendrocyte glycoprotein antibody‑associated disease (MOGAD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Satralizumab Approval Status for MOGAD

Satralizumab (Enspryng) is currently NOT approved for MOGAD and there is no publicly announced expected approval date. The drug is only FDA-approved for neuromyelitis optica spectrum disorder (NMOSD) in anti-aquaporin-4 (AQP4) antibody-positive adult patients 1.

Current Clinical Trial Landscape

While satralizumab remains investigational for MOGAD, several key points emerge from the available evidence:

Active Investigation

  • Satralizumab is among the targeted immunotherapies under active clinical investigation for MOGAD, alongside tocilizumab, azathioprine, and rozanolixizumab 2
  • The drug is being studied in ongoing phase 2/3 trials, though specific MOGAD trial names and completion dates are not detailed in the provided evidence 2

Mechanism and Rationale

The drug works as an IL-6 receptor antagonist, blocking interleukin-6-mediated signaling through binding to soluble and membrane-bound IL-6 receptors 1. This mechanism is theoretically relevant to MOGAD pathophysiology, though the precise therapeutic mechanism in demyelinating diseases remains incompletely understood 1.

Real-World Evidence in MOGAD

Recent observational data provides some insight into IL-6 receptor blockers (including satralizumab) for MOGAD:

  • A 2026 multicenter retrospective study included 116 MOGAD patients treated with IL-6 receptor blockers, of which only 12 (10%) received satralizumab (the remaining 90% received tocilizumab) 3
  • The study showed reduced annualized relapse rates with IL-6 receptor blockade, though the small satralizumab subset limits specific conclusions about this agent 3

Timeline Considerations

The evidence suggests regulatory approval may occur "in the next five years" if ongoing trials demonstrate efficacy and biomarker-driven strategies are refined 2. However, this represents expert speculation rather than confirmed regulatory timelines.

Critical Caveats

  • No approved therapies currently exist for MOGAD, making treatment empirical with significant variability in clinical response 2, 4, 5
  • The drug label explicitly states satralizumab's mechanism in NMOSD is "unknown but presumed" to involve IL-6 inhibition, and safety/efficacy in pediatric populations remain unestablished 1
  • Severe infections occurred in 9% of patients in observational MOGAD studies using IL-6 receptor blockers 3

For current clinical practice, satralizumab remains off-label for MOGAD and should only be considered in the context of clinical trials or when other evidence-based approaches have failed, given the lack of regulatory approval and limited MOGAD-specific safety data.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.